Clinical Trial: A Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of S247240 in Adult Male Participants With Fragile X Syndrome

U.S., Nov. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07930520) titled 'A Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of S247240 in Adult Male Participants With Fragile X Syndrome' on Nov. 04.

Brief Summary: This study is a multicenter, double-blind, randomized, placebo-controlled study to assess the safety and tolerability of 3 doses of S247240 in male participants with Fragile X Syndrome aged 18 to 45 years old. Participants will participate for 14 weeks of treatment. The study is also intended to characterize the PK profile of S247240 and to obtain preliminary assessments of the efficacy of S247240 in mental status examination scales and tests over the 14 weeks of treatment p...